Literature DB >> 8287966

Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.

O Wilhelm1, U Weidle, S Höhl, P Rettenberger, M Schmitt, H Graeff.   

Abstract

A recombinant soluble human urokinase receptor comprising amino acids 1-277 was cloned and transfected into CHO cells. The mutant protein (rec-uPAR277), purified from the CHO cell supernatant by affinity chromatography on immobilized urokinase (uPA), in a four-fold excess, completely abolished the binding of FITC-labeled pro-uPA to the human ovarian cancer cell line, OV-MZ-6. This invasive and tumorigenic cancer cell line expresses uPA, its inhibitor PAI-1, and the high-affinity receptor for uPA, uPAR. Rec-uPAR277 significantly reduced the proliferation of OV-MZ-6 cells in a concentration-dependent manner without altering the viability of the cells. Invasion of OV-MZ-6 cells tested in an in vitro Matrigel invasion assay was inhibited by rec-uPAR277 up to 75%. In conclusion, these results demonstrate that rec-uPAR277 can function as a scavenger for uPA in vitro by inhibiting proliferation and invasion of human cancer cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8287966     DOI: 10.1016/0014-5793(94)80259-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  19 in total

1.  An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.

Authors:  Shafaat A Rabbani; Bushra Ateeq; Ani Arakelian; Maria Luisa Valentino; David E Shaw; Lisa M Dauffenbach; Christopher A Kerfoot; Andrew P Mazar
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Invasion by esophageal cancer cells: functional contribution of the urokinase plasminogen activation system, and inhibition by antisense oligonucleotides to urokinase or urokinase receptor.

Authors:  D Morrissey; J O'Connell; D Lynch; G C O'Sullivan; F Shanahan; J K Collins
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

3.  Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors.

Authors:  Y Go; S K Chintala; S Mohanam; Z Gokaslan; B Venkaiah; R Bjerkvig; K Oka; G L Nicolson; R Sawaya; J S Rao
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

4.  Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression.

Authors:  N K Rao; G P Shi; H A Chapman
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

5.  A novel peptide blocking cancer cell invasion by structure-based drug design.

Authors:  Yuki Yamada; Seiji Kanayama; Fuminori Ito; Noriyuki Kurita; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-07-31

6.  Challenges for drug discovery - a case study of urokinase receptor inhibition.

Authors:  Zhuo Chen; Lin Lin; Qing Huai; Mingdong Huang
Journal:  Comb Chem High Throughput Screen       Date:  2009-12       Impact factor: 1.339

Review 7.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

8.  Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.

Authors:  T Luther; V Magdolen; S Albrecht; M Kasper; C Riemer; H Kessler; H Graeff; M Müller; M Schmitt
Journal:  Am J Pathol       Date:  1997-04       Impact factor: 4.307

9.  Inhibition of NF-kappa B-Rel A expression by antisense oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1.

Authors:  U Reuning; O Wilhelm; T Nishiguchi; L Guerrini; F Blasi; H Graeff; M Schmitt
Journal:  Nucleic Acids Res       Date:  1995-10-11       Impact factor: 16.971

10.  Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis.

Authors:  C E Holmes; J E Levis; D L Ornstein
Journal:  Clin Exp Metastasis       Date:  2009-05-15       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.